ArticleDrug and alcohol dependence reports2025
Clinically characterizing adults who use kava or kratom: Substance use disorder assessment challenges for increasingly popular botanical products.
Article in Drug and alcohol dependence reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Kava (Piper methysticum) consumption patterns and conceptualizations: results from an online survey.Substance abuse treatment, prevention, and policy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Kratom ( Methods: We conducted an online survey of US adults who have used kava or kratom. Diagnostic and Statistical Manual-5 (DSM-5) substance use disorder (SUD) criteria were used to assess symptoms related to past-year kratom and/or kava use. Respondents were also asked to report on the compatibility of kava and kratom effects with daily living. Results: Of the 367 participants, 91.3 % reported lifetime kratom use and 49.0 % reported lifetime kava use. There was substantial overlap of lifetime use of both substances (40.3 %). Past-year SUD diagnostic criteria for kratom were met by 38.1 % of participants; when this group was dichotomized by past-year kava use, those who also co-used kava had higher proportions of endorsing symptoms of "using more kratom than intended" and "needing to use larger amounts to feel the same effect" than those who used kratom without kava (p = 0.032 and p = 0.011, respectively). Meeting SUD criteria for kava was uncommon among those reporting past-year use (7.5 %), regardless of past-year kratom use. Kratom effects were perceived as helpful and compatible with daily living, though fewer reported this for kava effects. Conclusions: Assessment of patients using kratom or kava may become challenging due to co-use. The relative rewarding and reinforcing effects of these botanicals alone or combined requires systematic study. SUD for either is possible but should be contextualized by patient-level factors including other substance use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.